FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2961642254> ?p ?o ?g. }

• W2961642254 abstract "Objective: To assess the safety profile of lasmiditan based on findings from the Phase 3 studies, SPARTAN and SAMURAI. Background: Lasmiditan is a 5-HT1F receptor agonist without vasoconstrictive activity being developed as an acute therapy for migraine. SPARTAN and SAMURAI were double-blind studies of patients with migraine, randomized to oral lasmiditan 50mg (SPARTAN only), 100mg, 200mg, or placebo to be taken within 4 hours of onset of a migraine attack. If needed for rescue/recurrence, a second randomized dose could be taken. Design/Methods: Safety data from SPARTAN and SAMURAI were integrated. Treatment-emergent adverse events (TEAEs) (occurred within 48 hours of first dose, regardless of whether second dose taken) were considered in the analyses. Results: The safety population comprised 1262 participants assigned placebo, and 654, 1265, and 1258 assigned lasmiditan 50mg, 100mg, and 200mg, respectively. There were no deaths; serious adverse events were reported for 7 participants (placebo, n=2 [0.2%]; lasmiditan 50mg, n=1 [0.2%]; lasmiditan 100mg, n=1 [0.2%]; lasmiditan 200mg, n=3 [0.2%]). Participants reporting ≥1 TEAE were - Placebo, n=174 (13.5%); lasmiditan 50mg, n=166 (25.4%); lasmiditan 100mg, n=458 (36.2%); and lasmiditan 200mg, n=510 (40.3%). TEAEs were generally mild or moderate in severity. TEAEs in ≥2% of any lasmiditan dose group and more frequent with lasmiditan than placebo (p Conclusions: As a centrally-penetrant drug, lasmiditan use was associated with neurologic TEAEs most mild or moderate, of quick onset and self-limiting. Trial registration at clinicaltrials.gov: SAMURAI (NCT02439320) and SPARTAN (NCT02605174) Disclosure: Dr. Krege has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Krege has received compensation for serving on the Board of Directors of Eli Lilly and Company. Dr. Krege holds stock and/or stock options in Eli Lilly and Company. Dr. Liffick has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Doty has received personal compensation for consulting and serving on a scientific advisory board with Eli Lilly and Company, and has received personal compensation for speaking with the Allergan Botox Speakers Bureau, Amgen Speakers Bureau, and Teva Speakers Bureau. Dr. Doty holds stock and/or stock options in Eli Lilly and Company. Dr. Dowsett has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Wang has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Company. Dr. Buchanan has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Eli Lilly and Co." @default.
• W2961642254 created "2019-07-23" @default.
• W2961642254 creator A5013337549 @default.
• W2961642254 creator A5022238010 @default.
• W2961642254 creator A5030018731 @default.
• W2961642254 creator A5071267554 @default.
• W2961642254 creator A5078030274 @default.
• W2961642254 creator A5085694410 @default.
• W2961642254 date "2019-04-09" @default.
• W2961642254 modified "2023-09-27" @default.
• W2961642254 title "Safety Findings from the Phase 3 Studies (SAMURAI, SPARTAN) of Lasmiditan for Acute Treatment of Migraine (P1.10-009)" @default.
• W2961642254 hasPublicationYear "2019" @default.
• W2961642254 type Work @default.
• W2961642254 sameAs 2961642254 @default.
• W2961642254 citedByCount "0" @default.
• W2961642254 crossrefType "journal-article" @default.
• W2961642254 hasAuthorship W2961642254A5013337549 @default.
• W2961642254 hasAuthorship W2961642254A5022238010 @default.
• W2961642254 hasAuthorship W2961642254A5030018731 @default.
• W2961642254 hasAuthorship W2961642254A5071267554 @default.
• W2961642254 hasAuthorship W2961642254A5078030274 @default.
• W2961642254 hasAuthorship W2961642254A5085694410 @default.
• W2961642254 hasConcept C126322002 @default.
• W2961642254 hasConcept C142724271 @default.
• W2961642254 hasConcept C197934379 @default.
• W2961642254 hasConcept C204787440 @default.
• W2961642254 hasConcept C27081682 @default.
• W2961642254 hasConcept C2778541695 @default.
• W2961642254 hasConcept C42219234 @default.
• W2961642254 hasConcept C71924100 @default.
• W2961642254 hasConceptScore W2961642254C126322002 @default.
• W2961642254 hasConceptScore W2961642254C142724271 @default.
• W2961642254 hasConceptScore W2961642254C197934379 @default.
• W2961642254 hasConceptScore W2961642254C204787440 @default.
• W2961642254 hasConceptScore W2961642254C27081682 @default.
• W2961642254 hasConceptScore W2961642254C2778541695 @default.
• W2961642254 hasConceptScore W2961642254C42219234 @default.
• W2961642254 hasConceptScore W2961642254C71924100 @default.
• W2961642254 hasLocation W29616422541 @default.
• W2961642254 hasOpenAccess W2961642254 @default.
• W2961642254 hasPrimaryLocation W29616422541 @default.
• W2961642254 hasRelatedWork W2799749968 @default.
• W2961642254 hasRelatedWork W2800977241 @default.
• W2961642254 hasRelatedWork W2805440854 @default.
• W2961642254 hasRelatedWork W2808748844 @default.
• W2961642254 hasRelatedWork W2897284151 @default.
• W2961642254 hasRelatedWork W2900030708 @default.
• W2961642254 hasRelatedWork W2916037536 @default.
• W2961642254 hasRelatedWork W2950025797 @default.
• W2961642254 hasRelatedWork W2953644271 @default.
• W2961642254 hasRelatedWork W2982561889 @default.
• W2961642254 hasRelatedWork W3006211681 @default.
• W2961642254 hasRelatedWork W3093433847 @default.
• W2961642254 hasRelatedWork W3093820723 @default.
• W2961642254 hasRelatedWork W3111726044 @default.
• W2961642254 hasRelatedWork W3172467076 @default.
• W2961642254 hasRelatedWork W3183790588 @default.
• W2961642254 hasRelatedWork W3192908897 @default.
• W2961642254 hasRelatedWork W3196376434 @default.
• W2961642254 hasRelatedWork W3197720978 @default.
• W2961642254 hasRelatedWork W3120227962 @default.
• W2961642254 hasVolume "92" @default.
• W2961642254 isParatext "false" @default.
• W2961642254 isRetracted "false" @default.
• W2961642254 magId "2961642254" @default.
• W2961642254 workType "article" @default.